The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Gene Regulation and Chromatin Remodeling by IL-12 and Type I IFN in Programming for CD8 T Cell Effector Function and Memory
Open accessAbstract
A third signal that can be provided by IL-12 or type I IFN is required for differentiation of naive CD8 T cells responding to Ag and costimulation. The cytokines program development of function and memory within 3 days of initial stimulation, and we show here that programming involves regulation of a common set of ∼355 genes including T-bet and eomesodermin. Much of the gene regulation program is initiated in response to Ag and costimulation within 24 h but is then extinguished unless a cytokine signal is available. Histone deacetylase inhibitors mimic the effects of IL-12 or type I IFN signaling, indicating that the cytokines relieve repression and allow continued gene expression by promoting increased histone acetylation. In support of this, increased association of acetylated histones with the promoter loci of granzyme B and eomesodermin is shown to occur in response to IL-12, IFN-α, or histone deacetylase inhibitors. Thus, IL-12 and IFN-α/β enforce in common a complex gene regulation program that involves, at least in part, chromatin remodeling to allow sustained expression of a large number of genes critical for CD8 T cell function and memory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Effector CD8 + T Cell Function by the Transcription Factor Eomesodermin
Pearce, E. L., Mullen, A. C., Martins, G. A., Krawczyk, C. M., Hutchins, A. S., Zediak, V. P., Banica, M., DiCioccio, C. B., Gross, D. A., Mao, C.-A., et al. (2003) · Science · doi:10.1126/science.1090148 · Cited by 1,014
Cross-Presentation, Dendritic Cells, Tolerance and Immunity
Heath, W. R., & Carbone, F. R. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.47 · Cited by 882
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
Appay, V., Nixon, D. F., Donahoe, S. M., Gillespie, G. M. A., Dong, T., King, A., Ogg, G. S., Spiegel, H. M. L., Conlon, C., Spina, C. A., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.1.63 · Cited by 871
Cited by
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780
Transcriptional control of effector and memory CD8+ T cell differentiation
Kaech, S. M., & Cui, W. (2012) · Nature Reviews Immunology · doi:10.1038/nri3307 · Cited by 1,628
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Rao, R. R., Li, Q., Odunsi, K., & Shrikant, P. A. (2010) · Immunity · doi:10.1016/j.immuni.2009.10.010 · Cited by 656
“Because some studies suggest that type I IFNs (IFN-a and IFN-b), like IL-12, can also promote type I effector CD8+ T cell responses (Agarwal et al., 2009), we determined whether IFN-a could also regulate mTOR activity and T-bet expression in OT-I cells.”
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells
Kurtulus, S., Madi, A., Escobar, G., Klapholz, M., Nyman, J., Christian, E., Pawlak, M., Dionne, D., Xia, J., Rozenblatt-Rosen, O., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.11.014 · Cited by 636
Inflammatory cytokines as a third signal for T cell activation
Curtsinger, J. M., & Mescher, M. F. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.02.013 · Cited by 615
Self-citationDirect Effects of Type I Interferons on Cells of the Immune System
Hervas-Stubbs, S., Perez-Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Le Bon, A., & Melero, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1114 · Cited by 503
Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection
Crawford, A., Angelosanto, J. M., Kao, C., Doering, T. A., Odorizzi, P. M., Barnett, B. E., & Wherry, E. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.005 · Cited by 496
Regulation of antiviral T cell responses by type I interferons
Crouse, J., Kalinke, U., & Oxenius, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3806 · Cited by 479
Speiser, D. E., Chijioke, O., Schaeuble, K., & Münz, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00521-2 · Cited by 479
Cui, W., Liu, Y., Weinstein, J. S., Craft, J., & Kaech, S. M. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.017 · Cited by 410
Acetate Promotes T Cell Effector Function during Glucose Restriction
Qiu, J., Villa, M., Sanin, D. E., Buck, M. D., O’Sullivan, D., Ching, R., Matsushita, M., Grzes, K. M., Winkler, F., Chang, C.-H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.022 · Cited by 342
Transcriptional insights into the CD8+ T cell response to infection and memory T cell formation
The Immunological Genome Project Consortium, Best, J. A., Blair, D. A., Knell, J., Yang, E., Mayya, V., Doedens, A., Dustin, M. L., & Goldrath, A. W. (2013) · Nature Immunology · doi:10.1038/ni.2536 · Cited by 348
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
Basu, A., Ramamoorthi, G., Albert, G., Gallen, C., Beyer, A., Snyder, C., Koski, G., Disis, M. L., Czerniecki, B. J., & Kodumudi, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669474 · Cited by 321
The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis
Padgett, L. E., Broniowska, K. A., Hansen, P. A., Corbett, J. A., & Tse, H. M. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06826.x · Cited by 288
Generation of effector CD8+ T cells and their conversion to memory T cells
Cui, W., & Kaech, S. M. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00926.x · Cited by 286
The microRNA miR-155 controls CD8+ T cell responses by regulating interferon signaling
Gracias, D. T., Stelekati, E., Hope, J. L., Boesteanu, A. C., Doering, T. A., Norton, J., Mueller, Y. M., Fraietta, J. A., Wherry, E. J., Turner, M., et al. (2013) · Nature Immunology · doi:10.1038/ni.2576 · Cited by 277
Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma
Sharma, G., Ojha, R., Noguera-Ortega, E., Rebecca, V. W., Attanasio, J., Liu, S., Piao, S., Lee, J. J., Nicastri, M. C., Harper, S. L., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133225 · Cited by 80
Woods, D. M., Woan, K. V., Cheng, F., Sodré, A. L., Wang, D., Wu, Y., Wang, Z., Chen, J., Powers, J., Pinilla-Ibarz, J., et al. (2017) · Blood · doi:10.1182/blood-2016-08-731505 · Cited by 74
Van Hoecke, L., Roose, K., Ballegeer, M., Zhong, Z., Sanders, N. N., De Koker, S., Saelens, X., & Van Lint, S. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.09.004 · Cited by 55
Metadata
- Authors
- Agarwal, P., Raghavan, A., Nandiwada, S. L., Curtsinger, J. M., Bohjanen, P. R., Mueller, D. L., & Mescher, M. F.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08-01
- Volume
- 183
- Issue
- 3
- Pages
- 1695-1704
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1574046283
- Cited by
- 203
- References
- 3
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.